Docs Face Challenges Treating HPV Oropharyngeal CA Patients

This article originally appeared here.
Share this content:
Docs Face Challenges Treating HPV Oropharyngeal CA Patients
Docs Face Challenges Treating HPV Oropharyngeal CA Patients

FRIDAY, Oct. 31, 2014 (HealthDay News) -- Key challenges have been identified for health professionals communicating the role of human papillomavirus (HPV) in oropharyngeal squamous cell cancer (OSCC), according to a study published online Oct. 28 in Head & Neck.

Rachael H. Dodd, from University College London, and colleagues interviewed 15 health professionals caring for OSCC patients. Clinicians' experiences and the challenges of talking to patients about HPV were explored in a thematic analysis.

The researchers found that there were mixed views relating to explaining the causal role of HPV. Key messages to be communicated included normalizing HPV and emphasizing the positive prognosis associated with it. Managing couples in a consultation and patients' concerns about transmission of HPV to partners were identified as challenging experiences. Some clinicians reported limitations to their knowledge about HPV and identified a need for more information and training.

"The demographic characteristics of patients with HPV-OSCC present new challenges for health professionals in terms of the questions being asked, the factors important to the patients, and their rehabilitation and treatment needs," the authors write. "Experiences among health professionals differed, suggesting a need for clinical guidance for communication about HPV in this context to ensure that patients are receiving consistent messages."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths